Should newly-minted public biotechs be worried about a flood of stock impairing their stock prices following the post-IPO lockup expiry? The data suggests, in general, this isn’t a real concern: its more urban legend than reality
Fear Of The Flood: Post-IPO Lockup Expiry In Biotech
